Application of genomic technologies to DM skin and muscle samples has led to the hypothesis that DM pathology is caused by exposure to a type 1 interferon (IFN) that damages keratinocytes, myofibers, and capillaries (115–117). Here, IFNA1 is linked to dermatomyositis.